AbbVie’s (ABBV) shares weakened on Friday, despite the American drugmaker’s third-quarter fiscal year 2025 earnings surpassing Wall Street’s expectations. Take advantage of TipRanks Premium at 50% off ...
AbbVie’s solid stock performance is driven by rising investor optimism as the company has successfully navigated the loss of exclusivity (“LOE”) of its blockbuster drug, Humira, which once generated ...
AbbVie’s ABBV reported third-quarter 2025 results on Oct. 31, before market open. The company beat estimates for both earnings and sales. While sales rose 9.1% year over year, earnings declined 38% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback